Claims for Patent: 10,370,414

Summary for Patent: 10,370,414

Title:	Binding proteins comprising at least two repeat domains against HER2
Abstract:	The present invention relates to a recombinant binding protein comprising at least a first and a second repeat domain, wherein each of said two repeat domains binds the extracellular region of HER2 and wherein said repeat domains are covalently linked.
Inventor(s):	Fiedler; Ulrike (Lorrach, DE), Dolado; Ignacio (Rheinfelden, CH), Strobel; Heike (Zurich, CH)
Assignee:	Molecular Partners AG (Zurich-Schlieren, CH)
Application Number:	14/648,611
Patent Claims:	1. A recombinant protein comprising at least a first and a second ankyrin repeat domain, wherein each of said first and second ankyrin repeat domains binds the extracellular region of human epidermal growth factor receptor 2 (HER2), wherein said first ankyrin repeat domain binds domain II of HER2 and said second ankyrin repeat domain binds domain IV of HER2, wherein said first and second ankyrin repeat domains are located on the same polypeptide and wherein said first ankyrin repeat domain is located N-terminally to said second ankyrin repeat domain, and wherein a) said first ankyrin repeat domain comprises an amino acid sequence that has at least 91% amino acid sequence identity with an ankyrin repeat domain selected from the group consisting of SEQ ID NOs:62 to 68, 72, and 114 to 121, and b) said second ankyrin repeat domain comprises an amino acid sequence that has at least 91% amino acid sequence identity with an ankyrin repeat domain selected from the group consisting of SEQ ID NOs:74 to 82. 2. The recombinant protein of claim 1, wherein said first ankyrin repeat domain does not compete for binding to HER2 with pertuzumab. 3. The recombinant protein of claim 1, wherein said second ankyrin repeat domain does not compete for binding to HER2 with trastuzumab. 4. The recombinant protein of claim 1, wherein a) said first ankyrin repeat domain comprises an amino acid sequence that has at least 95% amino acid sequence identity with an ankyrin repeat domain selected from the group consisting of SEQ ID NOs:62 to 68, 72, and 114 to 121, and b) said second ankyrin repeat domain comprises an amino acid sequence that has at least 95% amino acid sequence identity with an ankyrin repeat domain selected from the group consisting of SEQ ID NOs:74 to 82. 5. The recombinant protein of claim 1, wherein said first ankyrin repeat domain binds the extracellular region of HER2 in PBS with a K.sub.d below 10.sup.-7M and said second ankyrin repeat domain binds the extracellular region of HER2 in PBS with a K.sub.d below 10.sup.-7M. 6. The recombinant protein of claim 1, wherein said protein inhibits stimulated proliferation of BT474 cells with an IC.sub.50 value below 100 nM. 7. The recombinant protein of claim 1, wherein said protein induces apoptosis in BT474 cells with an EC.sub.50 value below 100 nM. 8. The recombinant protein of claim 1, wherein said first and second ankyrin repeat domains are connected by a polypeptide linker. 9. The recombinant protein of claim 1, wherein a) said first ankyrin repeat domain comprises an amino acid sequence that has at least 98% amino acid sequence identity with an ankyrin repeat domain selected from the group consisting of SEQ ID NOs:62 to 68, 72, and 114 to 121, and b) said second ankyrin repeat domain comprises an amino acid sequence that has at least 98% amino acid sequence identity with an ankyrin repeat domain selected from the group consisting of SEQ ID NOs:74 to 82. 10. The recombinant protein of claim 1, wherein a) said first ankyrin repeat domain is selected from the group consisting of SEQ ID NOs:62 to 68, 72, and 114 to 121, and b) said second ankyrin repeat domain is selected from the group consisting of SEQ ID NOs:74 to 82, and wherein further a) G at position 1 and/or S at position 2 of said ankyrin repeat domains are optionally missing; and b) L at the second last position and/or N at the last position of said ankyrin repeat domains are optionally substituted with A. 11. A recombinant protein comprising at least a first and a second ankyrin repeat domain, wherein each of said two repeat domains binds the extracellular region of human epidermal growth factor receptor 2 (HER2), wherein said repeat domains are covalently linked, and wherein said recombinant protein comprises a polypeptide, wherein said polypeptide has at least 90% amino acid sequence identity with a polypeptide selected from the group consisting of SEQ ID NO:83 to 98, 102, 103, 122, 123, and 136 to 141. 12. A pharmaceutical formulation comprising a recombinant protein of claim 1 and a pharmaceutically acceptable carrier. 13. The recombinant protein of claim 11, wherein said first repeat domain binds domain II of HER2 and said second repeat domain binds domain IV of HER2, wherein said first and second repeat domains are located on the same polypeptide, and wherein said first repeat domain is located N-terminally to said second repeat domain. 14. The recombinant protein of claim 11, wherein said protein induces apoptosis in BT474 cells with an EC.sub.50 value below 100 nM. 15. The recombinant protein of claim 11, wherein said polypeptide has at least 95% amino acid sequence identity with a polypeptide selected from the group consisting of SEQ ID NO:83 to 98, 102, 103, 122, 123, and 136 to 141. 16. The recombinant protein of claim 11, wherein said polypeptide has at least 98% amino acid sequence identity with a polypeptide selected from the group consisting of SEQ ID NO:83 to 98, 102, 103, 122, 123, and 136 to 141. 17. A pharmaceutical formulation comprising the recombinant protein of claim 11 and a pharmaceutically acceptable carrier. 18. A recombinant protein comprising at least a first and a second ankyrin repeat domain, wherein each of said two repeat domains binds the extracellular region of human epidermal growth factor receptor 2 (HER2), wherein said repeat domains are covalently linked, and wherein said recombinant protein comprises a polypeptide, wherein said polypeptide comprises said first and second ankyrin repeat domains and has at least 90% amino acid sequence identity with SEQ ID NO: 87. 19. The recombinant protein of claim 18, wherein said polypeptide has at least 95% amino acid sequence identity with SEQ ID NO: 87. 20. The recombinant protein of claim 18, wherein said polypeptide has the amino acid sequence of SEQ ID NO: 87. 21. The recombinant protein of claim 18, wherein said protein induces apoptosis in BT474 cells with an EC.sub.50 value below 100 nM. 22. A pharmaceutical formulation comprising the recombinant protein of claim 18 and a pharmaceutically acceptable carrier. 23. A nucleic acid encoding the recombinant protein of claim 1.

Details for Patent 10,370,414

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2032-11-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2032-11-30
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012		2032-11-30
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2032-11-30